You are viewing an incomplete version of our website. Please click to reload the website as full version.

p53 antibody (Tumor Protein P53)

Details for Product anti-TP53 Antibody No. ABIN967422, Supplier: Log in to see
Antigen
  • tp53
  • p53
  • TP53
  • Tp53
  • bbl
  • bfy
  • bhy
  • p44
  • TpMs
  • BCC7
  • LFS1
  • P53
  • TRP53
  • Trp53
  • Xp53
  • brp53
  • drp53
  • etID22686.5
  • fb40d06
  • wu:fb40d06
  • zgc:111919
  • cellular tumor antigen p53
  • tumor protein p53
  • tumor supressor p53
  • p53 tumor suppressor
  • transformation related protein 53
  • transformation related protein 53, pseudogene
  • trichoplein, keratin filament binding
  • Wistar clone pR53P1 p53 pseudogene
  • CpipJ_CPIJ002758
  • TP53
  • tp53
  • P53
  • Trp53
  • Trp53-ps
  • TCHP
  • Tp53
  • p53-ps
Alternatives
anti-Human p53 antibody for Immunohistochemistry (Paraffin-embedded Sections)
Reactivity
Human
2212
496
410
170
130
94
69
64
35
23
18
17
17
16
16
11
5
4
4
4
4
3
3
3
2
1
Host
Mouse
1310
994
7
4
3
1
1
Clonality (Clone)
Monoclonal ()
Conjugate
This p53 antibody is un-conjugated
75
70
57
48
36
35
24
24
21
21
19
18
18
18
18
17
17
17
17
16
16
15
14
14
14
14
14
12
7
4
4
4
4
4
4
4
4
3
3
2
2
1
Application
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blotting (WB)
1782
751
660
587
534
473
411
267
258
179
55
41
34
31
18
17
15
15
13
12
11
9
8
4
4
3
3
2
2
2
1
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Brand BD Pharmingen™
Immunogen Recombinant fusion protein
Clone PAb 1801
Isotype IgG1
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name p53 (TP53 Antibody Abstract)
Background The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is over-expressed in a variety of transformed cells and it forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus and E6 from human papilloma virus. Recent data suggest that wild type p53 plays a role as a checkpoint protein for DNA damage during the S-phase of the cell cycle. However, it is still unclear whether point mutated forms of p53 are simple null mutants and/or dominant negatively acting proteins. p53 migrates at a reduced molecular weight of 53 kDa. Clone PAb 1801 recognizes an epitope between amino acids 32-79 in the N-terminal domain of human wild type and mutant p53 antibody. It does not cross-react with p53 from other species. A truncated recombinant human p53 fusion protein was used as immunogen.
Molecular Weight 53 kDa
Research Area Cancer, Cell Cycle, Transcription Factors, DNA/RNA, Apoptosis/Necrosis
Pathways p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding
Application Notes Applications include western blot analysis (1-2 µg/ml), immunoprecipitation (1-2 µg/1 x 10^6 cells), immunofluorescence microscopy of cultured cells, immunohistochemistry of frozen (5-20 µg/ml), and antigen-unmasked paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include SK-BR-3 human breast carcinoma cells (ATCC HTB-30), and A431 human vulval carcinoma cells (ATCC CRL-1555). COS-7 SV40 transformed monkey kidney cells (ATCC CRL-1651) or another SV40-transformed cell line are also useful as positive controls for detecting p53. MCF-7 human breast carcinoma cells (ATCC HTB-22) are suggested as a negative control. Positive immunostaining is seen in a high proportion of breast and colon carcinomas. p53 staining is not typically detected in normal skin, brain, kidney, lung, stomach or breast tissue.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4°C.
Supplier Images
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) image for anti-p53 antibody (Tumor Protein P53) (ABIN967422) Anti-human p53. Formalin-fixed, paraffin-embedded tissue section of breast carcinoma ...
Background publications Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, 1994 (PubMed).

Legros, Lacabanne, dAgay, Larsen, Pla, Soussi: "Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells." in: Bulletin du cancer, Vol. 80, Issue 2, pp. 102-10, 1994 (PubMed).

Said, Barrera, Shintaku, Nakamura, Koeffler: "Immunohistochemical analysis of p53 expression in malignant lymphomas." in: The American journal of pathology, Vol. 141, Issue 6, pp. 1343-8, 1993 (PubMed).

Porter, Gown, Kramp, Coltrera: "Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue." in: The American journal of pathology, Vol. 140, Issue 1, pp. 145-53, 1992 (PubMed).

Vojt?sek, Bártek, Midgley, Lane: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." in: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, 1992 (PubMed).

Walker, Dearing, Lane, Varley: "Expression of p53 protein in infiltrating and in-situ breast carcinomas." in: The Journal of pathology, Vol. 165, Issue 3, pp. 203-11, 1992 (PubMed).

Vogelstein: "Cancer. A deadly inheritance." in: Nature, Vol. 348, Issue 6303, pp. 681-2, 1991 (PubMed).

Baker, Markowitz, Fearon, Willson, Vogelstein: "Suppression of human colorectal carcinoma cell growth by wild-type p53." in: Science (New York, N.Y.), Vol. 249, Issue 4971, pp. 912-5, 1990 (PubMed).

Banks, Matlashewski, Crawford: "Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression." in: European journal of biochemistry / FEBS, Vol. 159, Issue 3, pp. 529-34, 1986 (PubMed).